In a report released today, Daina Graybosch from SVB Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $224.00. The company's shares closed last Thursday at $164.92, close to its 52-week low of $117.08. According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Century Therapeutics, and Bolt Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $221.30 average price target.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-biontech-ses-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more BioNTech Charts.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more BioNTech Charts.